NCT01173731

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's disease, L-dopa induced dyskinesias).

Conditions

• Parkinson Disease
• Dyskinesia, Drug-Induced
• Levodopa

Interventions

Type	Name	Description
DRUG	AFQ056

Timeline

• Start date: 2010-10-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2010-08-02
• Last updated: 2020-12-23

Locations

22 sites across 6 countries: United States, Australia, Canada, France, Germany, Italy